METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see how the drug…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:46 UTC
-
New Dual-Target pill shows promise against resistant cancers
Disease control Recruiting nowThis early-phase trial tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The drug targets two proteins to block cancer growth and overcome resistance. The main goals ar…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase: PHASE1 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated May 12, 2026 13:40 UTC